Drug Trial Radar · NCT07764965
Evaluation of PAN-90806 Eye Drops in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Dec 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- The Second Hospital of Anhui Medical University
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Health services research
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the safety, tolerability, and systemic pharmacokinetics of PAN-90806 eye drops in healthy adults. It will also evaluate what medical problems participants may have when taking PAN-90806. The main questions it aims to answer are: Is PAN-90806 eye drops safe and well tolerated in healthy participants? What are the systemic pharmacokinetic characteristics of PAN-90806 after ocular administration? What medical problems or adverse events do participants have when taking PAN-90806? Researchers will compare PAN-90806 eye drops to a placebo (a look-alike eye drop that contains no PAN-90806) to evaluate the safety, tolerability, and systemic pharmacokinetics of PAN-90806. Participants will: Receive PAN-90806 eye drops or placebo eye drops once daily in both eyes, one drop per eye, on Day 1 and Days 3 to 7, for a total of 6 dosing days Stay at the study center during the inpatient dosing period and attend scheduled study visits for screening, admission, dosing, and discharge Undergo blood sampling for pharmacokinetic testing, as well as eye examinations, laboratory tests, vital signs assessments, physical examinations, and ECGs
Conditions
- Wet Age Related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
Interventions
PAN-90806 Ophthalmic SolutionDrug
The medication was administered at 9:00am every morning on Day 1 and Day 3-Day 7 of hospitalization. Each time, the medication is administered to both eyes, 1 drop per eye, for a total of 6 days of treatment.
Vehicle Ophthalmic SolutionDrug
The medication was administered at 9:00am every morning on Day 1 and Day 3-Day 7 of hospitalization. Each time, the medication is administered to both eyes, 1 drop per eye, for a total of 6 days of treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Corneal endothelial cell examination (density(cells/mm2)Time frame: Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)
- Corneal endothelial cell examination (coefficient of variation(% of variation in total endothelial cell size ))Time frame: Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)
- Corneal endothelial cell examination(proportion of hexagonal cells(%))Time frame: Day-14~Day -1, and Day 9 (set Day 0 as the day hospitalized)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.